Pharmamarketeer

FDA approves Venclexta combo in acute myeloid leukaemia, despite it missing main study goal

Venclexta

The FDA has given approval to AbbVie and Roche’s jointly-developed BCL-2 inhibitor Venclexta (venetoclax) in combination with azacitidine, decitabine, or low-dose cytarabine as a treatment for newly-diagnosed acute myeloid leukaemia (AML) in patients at least 75 years old, or who have comorbidities that make the use of intensive induction chemotherapy inappropriate.

read more

Advertentie(s)